Nasdaq · CIK 0000874015
IONS IONIS PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing 40 d ago. Close $45.28 on Oct 9, 2026, +5% from the 52-week low and -48% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
IONSOct 9, 2026 · close 45.28
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at IONIS PHARMACEUTICALS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Joseph Baroldi EVP, Chief Business Officer sell | $743k 11,950 shares | -27% | +152% from low0% from high | |
| 18Weak | C Frank Bennett EVP, Chief Scientific Officer sell | $358k 6,000 shares | -7% | +140% from low0% from high | |
| 0Weak | Joseph Baroldi EVP, Chief Business Officer sell | $16k 250 shares | -1% | +140% from low0% from high | |
| 23Weak | C Frank Bennett EVP, Chief Scientific Officer sell | $2.3M 38,909 shares | -42% | +125% from low0% from high | |
| 33Weak | Joseph Baroldi EVP, Chief Business Officer sell | $1.9M 32,800 shares | -94% | +137% from low0% from high | |
| 0Weak | C Frank Bennett EVP, Chief Scientific Officer sell | $440k 10,000 shares | -10% | +70% from low-1% from high | |
| 43Moderate | Michael R Hayden director buy | $478k 15,000 shares | +43% | +24% from low-26% from high | |
| 30Weak | Joseph Baroldi EVP, Chief Business Officer sell | $112k 3,928 shares | -11% | +11% from low-34% from high | |
| 15Weak | Brian Birchler EVP, Corp and Development Ops sell | $19k 680 shares | -1% | +11% from low-34% from high | |
| 29Weak | Kyle Jenne EVP, Chf GL Pdt Str Ofcr sell | $86k 3,016 shares | -21% | +11% from low-34% from high | |
| 5Weak | Brett P Monia Chief Executive Officer sell | $4,525 140 shares | -0% | - | |
| 1Weak | Patrick R. O'Neil EVP CLO & General Counsel sell | $39k 1,207 shares | -2% | - | |
| 50Moderate | Brett P Monia Chief Executive Officer sell | $1.2M 38,843 shares | -18% | - | |
| 22Weak | Patrick R. O'Neil EVP CLO & General Counsel sell | $195k 6,165 shares | -10% | - | |
| 36Weak | C Frank Bennett EVP, Chief Scientific Officer sell | $43k 1,327 shares | -1% | - | |
| 36Weak | Richard S Geary EVP, Chief Development Officer sell | $46k 1,406 shares | -1% | - | |
| 44Moderate | Elizabeth L Hougen EVP, Finance & CFO sell | $49k 1,523 shares | -1% | - | |
| 57Moderate | Brett P Monia Chief Executive Officer sell | $430k 13,242 shares | -6% | - | |
| 36Weak | Patrick R. O'Neil EVP CLO & General Counsel sell | $46k 1,406 shares | -2% | - | |
| 37Weak | Eugene Schneider EVP, Chf Clinical Develop Ofcr sell | $48k 1,484 shares | -2% | - | |
| 36Weak | Eric Swayze EVP Research sell | $44k 1,367 shares | -3% | - | |
| 27Weak | C Frank Bennett EVP, Chief Scientific Officer sell | $222k 6,752 shares | -7% | - | |
| 31Weak | Joseph Baroldi EVP, Chief Business Officer sell | $145k 4,430 shares | -16% | - | |
| 27Weak | Brian Birchler EVP, Corp and Development Ops sell | $177k 5,400 shares | -9% | - | |
| 31Weak | Shannon L. Devers EVP, Chief Human Resources Ofc sell | $140k 4,267 shares | -21% | - | |
| 28Weak | Richard S Geary EVP, Chief Development Officer sell | $232k 7,072 shares | -7% | - | |
| 36Weak | Elizabeth L Hougen EVP, Finance & CFO sell | $291k 8,870 shares | -8% | - | |
| 55Moderate | Brett P Monia Chief Executive Officer sell | $1.1M 33,445 shares | -14% | - | |
| 33Weak | Patrick R. O'Neil EVP CLO & General Counsel sell | $242k 7,360 shares | -11% | - | |
| 32Weak | Eugene Schneider EVP, Chf Clinical Develop Ofcr sell | $214k 6,523 shares | -10% | - | |
| 33Weak | Eric Swayze EVP Research sell | $236k 7,176 shares | -14% | - | |
| 30Weak | Michael R Hayden director buy | $181k 5,000 shares | +17% | - | |
| 38Weak | Joseph Loscalzo director sell | $511k 13,508 shares | -30% | - | |
| 33Weak | Brett P Monia Chief Executive Officer sell | $252k 6,630 shares | -4% | - | |
| 16Weak | Eric Swayze EVP Research sell | $45k 1,194 shares | -3% | - | |
| 10Weak | Eric Swayze EVP Research sell | $2,031 53 shares | -25% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Brett P Monia Chief Executive Officer | JOther Common Stock | +98 | $51.31 | $5,028 | 242,760 | 40 d ago |
| Aug 31, 2026 | Brian Birchler EVP, Corp and Development Ops | JOther Common Stock | +58 | $51.31 | $2,976 | 102,883 | 40 d ago |
| Aug 31, 2026 | Patrick R. O'Neil EVP CLO & General Counsel | JOther Common Stock | +63 | $51.31 | $3,232 | 59,205 | 40 d ago |
| Aug 31, 2026 | C Frank Bennett EVP, Chief Scientific Officer | JOther Common Stock | +110 | $51.31 | $5,644 | 60,128 | 40 d ago |
| Sep 9, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Common Stock10b5-1 | +11,950 | $31.80 | $380k | 43,876 | Sep 11, 2025 |
| Sep 9, 2025 | Joseph Baroldi EVP, Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -11,950 | $62.16 | $743k | 31,926 | Sep 11, 2025 |
| Sep 9, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -11,950 | $0.00 | $0 | 41,700 | Sep 11, 2025 |
| Sep 5, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Common Stock10b5-1 | +250 | $31.80 | $7,950 | 32,176 | Sep 9, 2025 |
| Sep 5, 2025 | C Frank Bennett EVP, Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -6,000 | $59.60 | $358k | 82,679 | Sep 9, 2025 |
| Sep 5, 2025 | Joseph Baroldi EVP, Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -250 | $62.00 | $16k | 31,926 | Sep 9, 2025 |
| Sep 5, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -250 | $0.00 | $0 | 53,650 | Sep 9, 2025 |
| Sep 2, 2025 | C Frank Bennett EVP, Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -5,000 | $49.14 | $246k | 88,679 | Sep 4, 2025 |
| Sep 3, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Common Stock10b5-1 | +2,800 | $31.80 | $89k | 34,726 | Sep 4, 2025 |
| Sep 3, 2025 | Joseph Baroldi EVP, Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -2,800 | $62.01 | $174k | 31,926 | Sep 4, 2025 |
| Sep 3, 2025 | C Frank Bennett EVP, Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +46,800 | $53.77 | $2.5M | 135,479 | Sep 4, 2025 |
| Sep 3, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Common Stock10b5-1 | +15,000 | $31.80 | $477k | 46,926 | Sep 4, 2025 |
| Sep 3, 2025 | C Frank Bennett EVP, Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -33,909 | $60.62 | $2.1M | 101,570 | Sep 4, 2025 |
| Sep 3, 2025 | C Frank Bennett EVP, Chief Scientific Officer | MOption exercise Common Stock10b5-1 | -12,891 | $61.50 | $793k | 88,679 | Sep 4, 2025 |
| Sep 3, 2025 | Joseph Baroldi EVP, Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -30,000 | $59.09 | $1.8M | 16,926 | Sep 4, 2025 |
| Sep 3, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Common Stock10b5-1 | +15,000 | $31.80 | $477k | 31,926 | Sep 4, 2025 |
| Sep 3, 2025 | C Frank Bennett EVP, Chief Scientific Officer | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -46,800 | $0.00 | $0 | 0 | Sep 4, 2025 |
| Sep 3, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -2,800 | $0.00 | $0 | 83,900 | Sep 4, 2025 |
| Sep 3, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 68,900 | Sep 4, 2025 |
| Sep 3, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 53,900 | Sep 4, 2025 |
| Aug 29, 2025 | C Frank Bennett EVP, Chief Scientific Officer | JOther Common Stock | +213 | $27.71 | $5,902 | 93,679 | Sep 3, 2025 |
| Aug 29, 2025 | Brian Birchler EVP, Corp and Development Ops | JOther Common Stock | +166 | $27.71 | $4,600 | 56,826 | Sep 3, 2025 |
| Aug 18, 2025 | C Frank Bennett EVP, Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +10,000 | $32.60 | $326k | 103,466 | Aug 20, 2025 |
| Aug 18, 2025 | C Frank Bennett EVP, Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $43.98 | $440k | 93,466 | Aug 20, 2025 |
| Aug 18, 2025 | C Frank Bennett EVP, Chief Scientific Officer | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 18,869 | Aug 20, 2025 |
| Jul 15, 2025 | Spencer R Berthelsen director | MOption exercise Common Stock | +4,079 | $0.00 | $0 | 156,013 | Jul 17, 2025 |
| Jul 15, 2025 | Spencer R Berthelsen director | MOption exercise Restricted Stock Unitderivative | -4,079 | $0.00 | $0 | 5,220 | Jul 17, 2025 |
| Jul 1, 2025 | Spencer R Berthelsen director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +11,518 | $0.00 | $0 | 11,518 | Jul 2, 2025 |
| Jul 1, 2025 | Spencer R Berthelsen director | AGrant or award Restricted Stock Unitderivative | +5,220 | $0.00 | $0 | 9,299 | Jul 2, 2025 |
| May 1, 2025 | Michael R Hayden director | POpen-market purchase Common Stock | +15,000 | $31.86 | $478k | 50,219 | May 2, 2025 |
| Apr 15, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Common Stock | +10,837 | $0.00 | $0 | 35,854 | Apr 17, 2025 |
| Apr 15, 2025 | Kyle Jenne EVP, Chf GL Pdt Str Ofcr | MOption exercise Common Stock | +12,226 | $0.00 | $0 | 14,215 | Apr 17, 2025 |
| Apr 15, 2025 | Brian Birchler EVP, Corp and Development Ops | MOption exercise Common Stock | +1,875 | $0.00 | $0 | 57,340 | Apr 17, 2025 |
| Apr 16, 2025 | Joseph Baroldi EVP, Chief Business Officer | SOpen-market sale Common Stock | -3,928 | $28.40 | $112k | 31,926 | Apr 17, 2025 |
| Apr 16, 2025 | Brian Birchler EVP, Corp and Development Ops | SOpen-market sale Common Stock | -680 | $28.37 | $19k | 56,660 | Apr 17, 2025 |
| Apr 16, 2025 | Kyle Jenne EVP, Chf GL Pdt Str Ofcr | SOpen-market sale Common Stock | -3,016 | $28.36 | $86k | 11,199 | Apr 17, 2025 |
| Apr 15, 2025 | Brian Birchler EVP, Corp and Development Ops | MOption exercise Restricted Stock Unitderivative | -1,875 | $0.00 | $0 | 61,215 | Apr 17, 2025 |
| Apr 15, 2025 | Kyle Jenne EVP, Chf GL Pdt Str Ofcr | MOption exercise Restricted Stock Unitderivative | -12,226 | $0.00 | $0 | 36,677 | Apr 17, 2025 |
| Apr 15, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Restricted Stock Unitderivative | -10,837 | $0.00 | $0 | 66,511 | Apr 17, 2025 |
| Mar 11, 2025 | Brett P Monia Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -140 | $32.32 | $4,525 | 180,980 | Mar 13, 2025 |
| Feb 28, 2025 | Richard S Geary EVP, Chief Development Officer | JOther Common Stock | +415 | $28.21 | $12k | 99,492 | Mar 4, 2025 |
| Feb 28, 2025 | C Frank Bennett EVP, Chief Scientific Officer | JOther Common Stock | +320 | $28.21 | $9,028 | 93,466 | Mar 4, 2025 |
| Feb 28, 2025 | Brian Birchler EVP, Corp and Development Ops | JOther Common Stock | +414 | $28.21 | $12k | 55,465 | Mar 4, 2025 |
| Feb 28, 2025 | Eric Swayze EVP Research | JOther Common Stock | +415 | $28.21 | $12k | 48,432 | Mar 4, 2025 |
| Feb 28, 2025 | Brett P Monia Chief Executive Officer | JOther Common Stock | +437 | $28.21 | $12k | 181,120 | Mar 4, 2025 |
| Feb 28, 2025 | Patrick R. O'Neil EVP CLO & General Counsel | JOther Common Stock | +554 | $28.21 | $16k | 56,799 | Mar 4, 2025 |
| Feb 20, 2025 | Patrick R. O'Neil EVP CLO & General Counsel | SOpen-market sale Common Stock10b5-1 | -1,207 | $32.35 | $39k | 56,245 | Feb 24, 2025 |
| Feb 4, 2025 | Brett P Monia Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -38,843 | $31.65 | $1.2M | 180,683 | Feb 6, 2025 |
| Feb 4, 2025 | Patrick R. O'Neil EVP CLO & General Counsel | SOpen-market sale Common Stock10b5-1 | -6,165 | $31.62 | $195k | 57,452 | Feb 6, 2025 |
| Jan 30, 2025 | Brett P Monia Chief Executive Officer | AGrant or award Common Stock | +25,372 | $0.00 | $0 | 232,768 | Feb 3, 2025 |
| Jan 30, 2025 | Patrick R. O'Neil EVP CLO & General Counsel | AGrant or award Common Stock | +3,820 | $0.00 | $0 | 65,023 | Feb 3, 2025 |
| Jan 30, 2025 | Eugene Schneider EVP, Chf Clinical Develop Ofcr | AGrant or award Common Stock | +4,032 | $0.00 | $0 | 62,540 | Feb 3, 2025 |
| Jan 30, 2025 | Eric Swayze EVP Research | AGrant or award Common Stock | +3,714 | $0.00 | $0 | 49,384 | Feb 3, 2025 |
| Jan 30, 2025 | C Frank Bennett EVP, Chief Scientific Officer | AGrant or award Common Stock | +3,607 | $0.00 | $0 | 94,473 | Feb 3, 2025 |
| Jan 30, 2025 | Richard S Geary EVP, Chief Development Officer | AGrant or award Common Stock | +3,820 | $0.00 | $0 | 100,483 | Feb 3, 2025 |
| Jan 30, 2025 | Elizabeth L Hougen EVP, Finance & CFO | AGrant or award Common Stock | +4,138 | $0.00 | $0 | 112,023 | Feb 3, 2025 |
| Jan 31, 2025 | C Frank Bennett EVP, Chief Scientific Officer | SOpen-market sale Common Stock | -1,327 | $32.46 | $43k | 93,146 | Feb 3, 2025 |
| Jan 31, 2025 | Richard S Geary EVP, Chief Development Officer | SOpen-market sale Common Stock | -1,406 | $32.40 | $46k | 99,077 | Feb 3, 2025 |
| Jan 31, 2025 | Elizabeth L Hougen EVP, Finance & CFO | SOpen-market sale Common Stock | -1,523 | $32.44 | $49k | 110,500 | Feb 3, 2025 |
| Jan 31, 2025 | Brett P Monia Chief Executive Officer | SOpen-market sale Common Stock | -13,242 | $32.45 | $430k | 219,526 | Feb 3, 2025 |
| Jan 31, 2025 | Patrick R. O'Neil EVP CLO & General Counsel | SOpen-market sale Common Stock | -1,406 | $32.49 | $46k | 63,617 | Feb 3, 2025 |
| Jan 31, 2025 | Eugene Schneider EVP, Chf Clinical Develop Ofcr | SOpen-market sale Common Stock | -1,484 | $32.20 | $48k | 61,056 | Feb 3, 2025 |
| Jan 31, 2025 | Eric Swayze EVP Research | SOpen-market sale Common Stock | -1,367 | $32.31 | $44k | 48,017 | Feb 3, 2025 |
| Jan 15, 2025 | Eugene Schneider EVP, Chf Clinical Develop Ofcr | MOption exercise Common Stock | +17,372 | $0.00 | $0 | 65,031 | Jan 17, 2025 |
| Jan 15, 2025 | Brett P Monia Chief Executive Officer | MOption exercise Common Stock | +73,448 | $0.00 | $0 | 240,841 | Jan 17, 2025 |
| Jan 15, 2025 | Elizabeth L Hougen EVP, Finance & CFO | MOption exercise Common Stock | +23,887 | $0.00 | $0 | 116,755 | Jan 17, 2025 |
| Jan 15, 2025 | C Frank Bennett EVP, Chief Scientific Officer | MOption exercise Common Stock | +18,011 | $0.00 | $0 | 97,618 | Jan 17, 2025 |
| Jan 15, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Common Stock | +8,787 | $0.00 | $0 | 28,418 | Jan 17, 2025 |
| Jan 15, 2025 | Brian Birchler EVP, Corp and Development Ops | MOption exercise Common Stock | +14,283 | $0.00 | $0 | 60,451 | Jan 17, 2025 |
| Jan 15, 2025 | Patrick R. O'Neil EVP CLO & General Counsel | MOption exercise Common Stock | +19,690 | $0.00 | $0 | 68,563 | Jan 17, 2025 |
| Jan 15, 2025 | Kyle Jenne EVP, Chf GL Pdt Str Ofcr | AGrant or award Performance Restricted Stock Unitsderivative | +18,700 | $0.00 | $0 | 18,700 | Jan 17, 2025 |
| Jan 15, 2025 | Shannon L. Devers EVP, Chief Human Resources Ofc | MOption exercise Common Stock | +12,295 | $0.00 | $0 | 20,204 | Jan 17, 2025 |
| Jan 15, 2025 | Eric Swayze EVP Research | MOption exercise Common Stock | +19,111 | $0.00 | $0 | 52,824 | Jan 17, 2025 |
| Jan 15, 2025 | Richard S Geary EVP, Chief Development Officer | MOption exercise Common Stock | +18,901 | $0.00 | $0 | 103,735 | Jan 17, 2025 |
| Jan 15, 2025 | Michael J. Yang director | MOption exercise Common Stock | +1,931 | $0.00 | $0 | 1,931 | Jan 17, 2025 |
| Jan 16, 2025 | C Frank Bennett EVP, Chief Scientific Officer | SOpen-market sale Common Stock | -6,752 | $32.90 | $222k | 90,866 | Jan 17, 2025 |
| Jan 16, 2025 | Joseph Baroldi EVP, Chief Business Officer | SOpen-market sale Common Stock | -3,401 | $32.70 | $111k | 25,017 | Jan 17, 2025 |
| Jan 16, 2025 | Brian Birchler EVP, Corp and Development Ops | SOpen-market sale Common Stock | -5,400 | $32.70 | $177k | 55,051 | Jan 17, 2025 |
| Jan 16, 2025 | Shannon L. Devers EVP, Chief Human Resources Ofc | SOpen-market sale Common Stock | -4,267 | $32.78 | $140k | 15,937 | Jan 17, 2025 |
| Jan 16, 2025 | Richard S Geary EVP, Chief Development Officer | SOpen-market sale Common Stock | -7,072 | $32.86 | $232k | 96,663 | Jan 17, 2025 |
| Jan 16, 2025 | Elizabeth L Hougen EVP, Finance & CFO | SOpen-market sale Common Stock | -8,870 | $32.81 | $291k | 107,885 | Jan 17, 2025 |
| Jan 16, 2025 | Brett P Monia Chief Executive Officer | SOpen-market sale Common Stock | -33,445 | $32.63 | $1.1M | 207,396 | Jan 17, 2025 |
| Jan 16, 2025 | Patrick R. O'Neil EVP CLO & General Counsel | SOpen-market sale Common Stock | -7,360 | $32.83 | $242k | 61,203 | Jan 17, 2025 |
| Jan 16, 2025 | Eugene Schneider EVP, Chf Clinical Develop Ofcr | SOpen-market sale Common Stock | -6,523 | $32.79 | $214k | 58,508 | Jan 17, 2025 |
| Jan 16, 2025 | Eric Swayze EVP Research | SOpen-market sale Common Stock | -7,154 | $32.84 | $235k | 45,670 | Jan 17, 2025 |
| Jan 15, 2025 | Kyle Jenne EVP, Chf GL Pdt Str Ofcr | AGrant or award Restricted Stock Unitderivative | +28,050 | $0.00 | $0 | 28,050 | Jan 17, 2025 |
| Jan 15, 2025 | Michael J. Yang director | MOption exercise Restricted Stock Unitderivative | -1,931 | $0.00 | $0 | 7,939 | Jan 17, 2025 |
| Jan 15, 2025 | C Frank Bennett EVP, Chief Scientific Officer | AGrant or award Performance Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 63,482 | Jan 17, 2025 |
| Jan 15, 2025 | Joseph Baroldi EVP, Chief Business Officer | MOption exercise Common Stockindirect: by Spouse | +2,460 | $0.00 | $0 | 4,100 | Jan 17, 2025 |
| Jan 15, 2025 | Brian Birchler EVP, Corp and Development Ops | AGrant or award Performance Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 53,338 | Jan 17, 2025 |
| Jan 15, 2025 | Shannon L. Devers EVP, Chief Human Resources Ofc | AGrant or award Performance Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 22,000 | Jan 17, 2025 |
| Jan 15, 2025 | Eric Swayze EVP Research | MOption exercise Common Stockindirect: by Son | +49 | $0.00 | $0 | 206 | Jan 17, 2025 |
| Jan 15, 2025 | Eugene Schneider EVP, Chf Clinical Develop Ofcr | AGrant or award Performance Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 65,437 | Jan 17, 2025 |
| Jan 15, 2025 | Patrick R. O'Neil EVP CLO & General Counsel | AGrant or award Performance Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 64,801 | Jan 17, 2025 |
| Jan 15, 2025 | Brett P Monia Chief Executive Officer | AGrant or award Performance Restricted Stock Unitsderivative | +169,950 | $0.00 | $0 | 630,201 | Jan 17, 2025 |
| Jan 15, 2025 | Elizabeth L Hougen EVP, Finance & CFO | AGrant or award Performance Restricted Stock Unitsderivative | +31,000 | $0.00 | $0 | 86,635 | Jan 17, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- C Frank BennettEVP, Chief Scientific Officer
- Spencer R Berthelsendirector
- Joseph BaroldiEVP, Chief Business Officer
- Brian BirchlerEVP, Corp and Development Ops
- Shannon L. DeversEVP, Chief Human Resources Ofc
- Richard S GearyEVP, Chief Development Officer
- Elizabeth L HougenEVP, Finance & CFO
- Michael R Haydendirector
- Kyle JenneEVP, Chf GL Pdt Str Ofcr
- Joseph Loscalzodirector
- Brett P MoniaChief Executive Officer
- Patrick R. O'NeilEVP CLO & General Counsel
- Eugene SchneiderEVP, Chf Clinical Develop Ofcr
- Eric SwayzeEVP Research
- Michael J. Yangdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.